Evolent Health Inc

Evolent Health Inc (EVH) Stock Analysis

$4.530

-0.255 (-5.62%)At close

Loading chart…
High
4.850
Open
4.790
VWAP
4.58
Volume
1.73M
Mkt Cap
2.30B
Low
4.360
Amount
7.93M
EV/EBITDA, TTM
20.54

Evolent Health, Inc. is a health care company connecting care for people with complex conditions like cancer, cardiovascular disease, and musculoskeletal diagnoses. The Company offers primary solutions, including specialty care management services and administrative services. It provides comprehensive quality management for oncology and cardiology patients from diagnosis through advanced care planning services, as well as identifying quality, lowest cost of care for outpatient orthopedic surgeries. Its administrative services solution includes an integrated value-based care platform designed to help customers manage and administer patient health in a cost-effective manner.

AI analysis of Evolent Health Inc (EVH)

Buy

Evolent Health Inc is a good buy right now due to its recent price performance and favorable technical indicators. The current price is $4.8, with a recent 5-day change of +5.03% and a 20-day change of +32.96%. The RSI is at 63.566, indicating bullish momentum. However, the main risk is the high net debt-to-EBITDA ratio of 7x, which could lead to capital raising under unfavorable conditions.

Analyst Ratings (13)

+105.96% upside
Buy
13 Buy
0 Hold
0 Sell
Current: 4.53
Low
5.00
Average
9.33
High
16.00

Citi

2026-08-10

Price Target

$6

Buy

Canaccord

2026-08-10

Price Target

$6

Buy

TD Cowen

2026-07-28

Price Target

$5

Buy

Citi

2026-07-23

Price Target

—

Neutral

Canaccord

2026-07-21

Price Target

$7

Buy

Valuation Metrics

The current forward P/E ratio for Evolent Health Inc (EVH) is 8.62, compared to its 5-year average forward P/E of 68.39.

Forward P/E

Fair
5Y Average P/E
68.39
Current P/E
8.62
Overvalued
239.79
Undervalued
-103.01

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-3976.34
Current EV/EBITDA
20.54
Overvalued
24964.91
Undervalued
-32917.58

Forward P/S

Undervalued
5Y Average P/S
1.11
Current P/S
0.17
Overvalued
1.83
Undervalued
0.39

Alphio AI Price Scenarios for EVH

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%EVH

$10.23

Scenario price

B

Base

Base · 50%EVH

$8.49

Scenario price

B

Bear

Bear · 25%EVH

$7.28

Scenario price

Whales holding EVH

R

Rock Springs Capital Management LP

+ HoldingEVH

-9.72%

3M Return

Events Timeline

2026-08-06 (ET)

08:00:00

Evolent Reports Q2 Revenue of $652.52M, Beating Consensus

08:00:00

2026 Revenue Consensus at $2.5B, Adjusted EBITDA Guidance Tightened to $120M-$135M

2026-05-07 (ET)

07:30:00

Evolent Q1 Revenue at $496.25M, Below Consensus

2026-03-19 (ET)

09:00:00

Evolent Health Appoints Archie Mayani as Chief Product Officer

2026-03-02 (ET)

07:40:00

Oppenheimer Lowers Evolent Health Price Target to $6

News

EVH FAQ — answered by Alphio AI

Evolent Health, Inc. is a health care company connecting care for people with complex conditions like cancer, cardiovascular disease, and musculoskeletal diagnoses. The Company offers primary solutions, including specialty care management services and administrative services. It provides comprehensive quality management for oncology and cardiology patients from diagnosis through advanced care planning services, as well as identifying quality, lowest cost of care for outpatient orthopedic surgeries. Its administrative services solution includes an integrated value-based care platform designed to help customers manage and administer patient health in a cost-effective manner. It operates in the Healthcare sector (SERVICES-MANAGEMENT SERVICES industry).

Evolent Health Inc is a good buy right now due to its recent price performance and favorable technical indicators. The current price is $4.8, with a recent 5-day change of +5.03% and a 20-day change of +32.96%. The RSI is at 63.566, indicating bullish momentum. However, the main risk is the high net debt-to-EBITDA ratio of 7x, which could lead to capital raising under unfavorable conditions.

13 analysts cover EVH: 13 rate it Buy, 0 Hold and 0 Sell. The average price target is 9.33.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading